Burkitt lymphoma : diagnosis, risk factors and treatment / Douglas V. Berthelot, editor.

Format:

Book

Contributor:

Berthelot, Douglas V., editor.

Series:

Cancer etiology, diagnosis, and treatments.

Cancer Etiology, Diagnosis and Treatments

Language:

English

Subjects (All):

Burkitt's lymphoma.

Physical Description:

1 online resource (274 pages)

Place of Publication:

New York : Nova Science Publishers, Inc., [2021]

Summary:

"Burkitt lymphoma (BL) is a form of non-Hodgkin's lymphoma in which cancer starts in immune cells called B-cells. If left untreated, it is rapidly fatal. Chapter One of this monograph evaluates the etiology, pathological issues, diagnosis, clinical manifestations, epidemiology, research, innovation and treatment issues of BL using the clinical systematic review research method and experts' opinion analysis approach. Chapter Two reviews the spectrum, unique characteristics and special management considerations when BL develops in specific subgroups of patients with primary immune deficiency disorders. Chapter Three reviews the incidence, clinicopathological and epidemiologic features, treatment and outcome data available in pediatric and adult patients with post solid organ transplant BL. Chapter Four focuses on the pathobiology and the treatment of first-line and relapsed/refractory cases of BL and describes new therapeutic strategies which could improve results in this pathology. Chapter Five examines the therapeutic advances in BL and its variants. Finally, Chapter Six explores and emphasizes the trends and issues in research and innovation in the characteristics, clinical updates and management approaches of BL"-- Provided by publisher.

Contents:

Intro

Contents

Preface

Chapter 1

Burkitt Lymphoma: Diagnosis and Treatment Issues

Abstract

Introduction

Methods

Inclusion Criteria

Data Extraction

Methodological Quality

Data and Statistical Analysis

Results

Classification of Burkitt Lymphoma

The Endemic Type (Which Is Also Known as "African Variant")

The Sporadic Type of BL (Also Known as "Non-African" Variant)

Immunodeficiency-Associated BL

Etiology of BL

Symptoms of BL

Epidemiology of BL

Epidemiologic Features of Endemic, Sporadic and AIDS-Associated BL

Pathophysiology

Genetics

MicroRNA Expression

BL Pathogenesis and EBV Manifestation

The Roles of Holoendemic Malaria and HIV Infection in BL Pathogenesis

Histopathology

Patient History and Physical Examination

Diagnosis of BL

Characteristics/Features of Malignant B Cells

Microscopic Investigations

Immunohistochemistry Analysis

Evaluation and Laboratory Tests for Patients

Staging of BL

St. Jude/Murphy Staging System in Children

Stage I

Stage II

Stage III

Stage IV

The Murphy Staging System in Adults

Stage HR (Hormone Receptor Stage)

Stage III A

Stage III B

Ann Arbor System in Adult

Differential Diagnosis

Risk Factors for BL

Treatment and Management Issues

Toxicity and Side Effect Management

Complications of BL

Prognosis of BL

Multi-Professional Healthcare Team Management Need

Research and Innovations in the Diagnosis and Treatment Advances of Bl

Research in Diagnostic Advances of BL

Gene Targets

Issues in BL Pathogenesis and Cellular Genetic Change

The Effects of C-Myc Overexpression and C-Myc Translocation

Research Efforts and Updates on Myc Gene.

Mechanisms Whereby C-Myc Drives BL Tumorigenesis

Recent Studies to Determine the Role of C-Myc in Tumorigenesis

Matters in Histologic Diagnosis of BL

Recent Advances in the Molecular Diagnosis of BL

Research in the Treatment Advances of BL

Revelation of New Approaches to Burkitt Lymphoma Treatment and Management

Less Toxic Alternative to Standard Treatment for Adults with BL

Discussion

Conclusion

References

Biographical Sketches

Chapter 2

Burkitt Lymphoma in Patients with Primary Immunodeficiency Disorders

1. Introduction

2. Clinical Cases

2.1. Case-1 [15]

2.2. Case 2 [16]

3. Epidemiology

3.1. Data from Large PIDs Registries

3.2. Age and Gender Distribution

3.3. Burkitt Lymphoma in Patients with PIDs

4. Lymphomagenesis in Immune Deficiency Disorders

4.1. Cancer Immune Surveillance in Immune Deficiency Disorders

4.2. EBV and PIDs-Associated Lymphoma

4.3. Mechanisms of Lymphomagenesis in PIDs

5. Primary Immune Deficiency Disorders Commonly Associated with Lymphoma

5.1. Chromosome Instability Syndromes

5.1.1. Ataxia Telangiectasia (AT)

5.1.2. Nijmegen Breakage Syndrome (NBS)

5.1.3. Bloom Syndrome (BS)

5.2. Wiskott-Aldrich Syndrome (WAS)

5.3. Common Variable Immunodeficiency (CVID)

5.4. X-linked Lymphoproliferative Disease Type 1 (XLP1)

5.5. Other PIDs Associated with Burkitt Lymphoma

6. Treatment Considerations

6.1. Index of Suspicion of PIDs in Newly Diagnosed B-NHL

6.2. Chemotherapy

6.3. Special Treatment Considerations in PIDs Associated BL

6.3.1. Chromosome Instability Syndromes

6.3.2. Ataxia Telangiectasia and Nijmegen Breakage Syndrome

6.3.3. Nijmegen Breakage Syndrome

6.3.4. Bloom Syndrome

6.3.5. Wiscott Aldrich Syndrome

6.3.6. X-linked Lymphoproliferative Disease Type 1.

6.4. Treatment Modalities Other Than Chemotherapy

6.4.1. Targeted Immunotherapy

6.4.2. EBV Specific Cytotoxic T cells

6.4.3. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

7. Unique Long Term Risks

7.1. Malignancies

7.2. Chronic Lung Disease

Conclusion and Future Perspectives

Acknowledgments

Biographical Sketch

Chapter 3

Post Solid Organ Transplant Burkitt Lymphoma

2. Epidemiology

2.2. Transplant Risk Factors

3. Biopathology

3.1. Pathologic and Genetic Features

3.2. The Role of EBV in PTLD and PSOT-BL

3.3. Epstein-Barr Virus DNAemia Load

4. Clinical Features and Involved Sites

5. Treatment

5.1. Are Treatment Strategies for M-PTLD Effective in BL?

5.2. Response Based Treatment Strategies

5.3. Chemotherapy Intensity in PSOT-BL

5.4. Cytotoxic T Cell in PTLD and BL

5.5. CAR-T in PTLD and PSOT-BL

6. Prognostic Factors

7. Outcome

7.1. Potential Long-Term Effects and Need for Therapy Modifications

8. Organ Specific Treatment Considerations

8.1. Cardiac

8.2. Renal and Hepatic Toxicity

Conclusion and Perspectives

Acknowledgements

Chapter 4

Burkitt Lymphoma

Epidemiology

Pathobiology

Clinical Presentation

Diagnosis

Prognosis

Treatment

First-Line Therapy for BL

Treatment Regimen in the Context of CNS Involvement

Treatment of Relapsed and Refractory BL

Targeted Therapies

Chimeric Antigen Receptor (CAR) T-Cell Therapy

Bispecific T-Cell Engagers (BiTEs)

Chapter 5

Examining the Therapeutic Advances for Burkitt Lymphoma

Etiology/Causes of BL

Types of BL

Endemic BL

Sporadic BL

Immunodeficiency-Related BL

Epidemiology of BL.

Clinical Presentations of BL

Clinical Evaluations of BL

EBV and BL

Determination of the Staging of BL

Histology/Morphology and Cytogenetics

Immunophenotype and Molecular Signature

Treatment Choices for BL

Chemotherapy

Targeted Therapy

Central Nervous System Prophylaxis

Progress on the Role of HSCT in the Treatment of BL

Progress on Exploring the Use of Immunotherapy and Experimental Agents in the Treatment of BL

The Effect of Ofatumumab and Obinutuzumab GA101

Chimeric Antigen Receptor (CAR T-Cell)

Immune-Checkpoint (PD-1 - PD-L1)

Future Directions in MYC Inhibition

Progress on New Finding Therapies for BL

Prognosis of Therapies

Chapter 6

Burkitt Lymphoma: Evaluation of Characteristics, Clinical Updates and Management Approaches Trends

Clinical Characteristics and Manifestations

Epidemiological Updates

Diagnosis Updates

Trends in the Management Approaches of BL

Progress on DA-EPOCH-R

Situation of When a Patient Is Too Ill to Receive Chemotherapy

When There Is a Lack of Referral to a Specialist/Secondary/Tertiary Care Unit

Updates on Prognosis of BL

Index

Blank Page.

Notes:

Description based on print version record.

ISBN:

1-68507-083-3